Moderna and Merck Report Major Win: Personalized mRNA Vaccine With Keytruda Cuts Melanoma Recurrence

Merck and Moderna announced promising results from a large trial showing that a personalized mRNA vaccine given with Merck’s immunotherapy Keytruda reduced the risk that melanoma would return or spread after surgery. The trial enrolled more than 1,000 patients with localized melanoma who were at high risk of relapse after tumor removal.

The investigational regimen, called intismeran autogene, combines up to nine doses of Keytruda (infused every six weeks) with up to nine doses of a bespoke mRNA vaccine that trains the immune system to recognize tumor-specific mutations. By comparison, Keytruda given alone as adjuvant therapy is typically administered every three to six weeks for up to a year.

What the Data Show

Company statements reported a reduction in both recurrence and distant spread of disease versus Keytruda alone, and they said no new safety signals emerged when the vaccine was added. The full trial dataset and peer-reviewed publication have not yet been released, and investigators will continue following participants to assess whether the combination improves overall survival.

These large-trial results build on earlier five-year data from a mid-stage study presented in June, which showed the vaccine roughly halved the risk of relapse and reduced the risk of metastasis by about 59% compared with Keytruda alone. That mid-stage study likewise reported no new increase in serious adverse events when the vaccine was combined with Keytruda.

Why This Matters

Unlike chemotherapy, which damages healthy as well as cancerous cells, or broad-spectrum immune checkpoint inhibitors that broadly stimulate immune responses, personalized cancer vaccines are designed to teach the immune system to target mutations found only in an individual patient’s tumor. Melanoma was a natural early test case because it typically carries a high mutational burden, making tumor-specific targets easier to identify.

“It is a big deal for the field in general,” said Dr. Ryan Sullivan of Mass General Brigham. Dr. Julie Gralow of ASCO called the result “a monumental leap forward,” noting it helps validate mRNA technology as a cancer treatment approach.

Broader Development And Timelines

Merck and Moderna are expanding trials into other cancers: large studies in surgically resected non‑small cell lung cancer and mid‑ or early‑stage trials in bladder, kidney, pancreatic and stomach cancers. Moderna has said multiple readouts are expected over the next one to two years.

Roche and BioNTech are developing a related personalized mRNA approach (autogene cevumeran) with mid‑stage colon and pancreatic cancer trials; Roche expects colon trial results in 2027 and pancreatic results in 2031.

Safety And Next Steps

Reported side effects so far were consistent with typical vaccine reactions and known Keytruda toxicities—fatigue, diarrhea, rash and immune‑related inflammation of joints, muscles or organs. No novel safety concerns were announced. Key outstanding questions include the durability of benefit, effects on overall survival, and how broadly the approach will translate across tumor types and patient risk groups.

The trial is ongoing; full data and peer‑reviewed publications will be important for regulators, clinicians and patients considering the balance of benefits and risks.